drugset
drugset / Trial / NCT07105592

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

NCT07105592 ↗

Phase 1/2 Recruiting 68 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, Phase Ib/II clinical study to evaluate the safety and efficacy of nimotuzumab combined with adebrelimab and chemotherapy in patients with recurrent and metastatic head and neck squamous cell carcinoma who are ineligible to high-dose cisplatin treatment.

Timeline

Start
2025-05-13
Primary completion
2027-05-31
Completion
2029-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 200 mg Intravenous
Subject Nimotuzumab Monoclonal antibody 400 mg Intravenous
Subject Nimotuzumab Monoclonal antibody 600 mg Intravenous
Background Adebrelimab Monoclonal antibody 1200 mg Intravenous
Background Carboplatin Small molecule 2 unknown Intravenous
Background Paclitaxel Small molecule 100 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma